Intellia Therapeutics (NTLA): Raising PT - Chardan

Chardan Capital Markets analyst, Madhu Kumar, reiterated his Buy rating on shares of Intellia Therapeutics (NASDAQ: NTLA) and raised his price target to $20 after the company announced 2Q17 results along with a corporate update. The company highlighted recent progress, including
preclinical data (in a program in partnership with Neutral-rated Regeneron) that demonstrated suppression of transthyretin (TTR) using TTR-directed CRISPR guide RNAs along with Cas9.

The analyst stated "In light of model updates in response to 2Q17 results, we have raised our price target to $20 (from $19) and reiterate our Buy rating".

For an analyst ratings summary and ratings history on Intellia Therapeutics click here. For more ratings news on Intellia Therapeutics click here.

Shares of Intellia Therapeutics closed at $16.11 yesterday.

You May Also Be Interested In

• Viking Holdings (VIK) PT Raised to $82 at Mizuho
• Nutanix (NTNX) PT Raised to $80 at Oppenheimer Into EPS
• Rubrik Inc (RBRK) PT Raised to $120 at Oppenheimer; Sees Another 'Beat and Raise'